Suritozole
Suritozole is a pharmacological agent that was under investigation for the treatment of Alzheimer's disease. It is a GABA antagonist, specifically a GABA_A receptor antagonist.
History[edit | edit source]
Suritozole was developed by the pharmaceutical company Eli Lilly and Company. It was investigated as a potential treatment for Alzheimer's disease, but development was discontinued due to lack of efficacy in clinical trials.
Mechanism of Action[edit | edit source]
Suritozole acts as a GABA_A receptor antagonist. The GABA_A receptor is a type of GABA receptor that responds to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory compound in the mature vertebrate central nervous system. By blocking these receptors, suritozole may increase neuronal activity in certain areas of the brain.
Clinical Trials[edit | edit source]
Clinical trials for suritozole were conducted to evaluate its efficacy in treating Alzheimer's disease. However, the results did not show significant improvement in patients' cognitive function or daily living activities. As a result, development of the drug was discontinued.
See Also[edit | edit source]
References[edit | edit source]
Suritozole Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD